Celgene, Accord settle Revlimid patent litigation

Celgene Corp. (NASDAQ:CELG) granted Accord Healthcare Ltd. (Middlesex, U.K.) rights to market an authorized generic version of cancer and

Read the full 194 word article

User Sign In